Johnson & Johnson ($JNJ) Stock Forecast: Up 2.8% Today

What is Johnson & Johnson?

Johnson & Johnson (JNJ) is a renowned pharmaceutical and healthcare company, known for its diverse range of products including medical devices, pharmaceuticals, and consumer goods. The stock had a strong bullish movement today.

Why is Johnson & Johnson going up?

JNJ stock is up 2.8% on Oct 15, 2024 14:36

• Johnson & Johnson reported impressive Q3 earnings with both revenue and EPS beating expectations, driven by strong sales of cancer drugs.
• The revision of annual outlook to reflect the V-Wave acquisition also contributed to the positive sentiment surrounding the stock.
• Analysts revising their forecasts ahead of the earnings call and high-rolling investors positioning themselves bullish on JNJ further added to the optimism in the market.
• The overall positive earnings report and strategic acquisitions seem to have fueled investor confidence, leading to the bullish movement in Johnson & Johnson's stock price today.

JNJ Price Chart

JNJ Technical Analysis

JNJ News

Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition - Johnson & Johnson ( NYSE:JNJ )

On Tuesday, Johnson & Johnson JNJ reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.

https://www.benzinga.com/general/biotech/24/10/41329767/johnson-johnsons-q3-earnings-revenue-and-eps-beat-on-strong-cancer-drug-sales-revises-annual-outl

Johnson & Johnson ( JNJ ) Tops Q3 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.01% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2350389/johnson-johnson-jnj-tops-q3-earnings-and-revenue-estimates

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Johnson & Johnson ( NYSE:JNJ )

Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15. Analysts expect the New Brunswick, New Jersey-based bank to report quarterly earnings at $2.21 per share, down from $2.66 per share in the year-ago period.

https://www.benzinga.com/news/earnings/24/10/41318794/johnson-johnson-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnin

This Is What Whales Are Betting On Johnson & Johnson - Johnson & Johnson ( NYSE:JNJ )

High-rolling investors have positioned themselves bullish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.

https://www.benzinga.com/insights/options/24/10/41318755/this-is-what-whales-are-betting-on-johnson-johnson

Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals - Johnson & Johnson ( NYSE:JNJ )

Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share ( EPS ) of $2.21 and revenue of $22.16 billion.

https://www.benzinga.com/general/biotech/24/10/41313932/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals

Trending Today

XRP ($XRP) Crypto Forecast: Up 7.2% Today

The Sandbox ($SAND) Crypto Forecast: Down 5.0% Today

Arbitrum ($ARB) Crypto Forecast: Down 5.2% Today

Horizen ($ZEN) Crypto Forecast: Up 5.2% Today

Pepe ($PEPE) Crypto Forecast: Down 8.2% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Bonk ($BONK) Crypto Forecast: Down 6.7% Today

Blur ($BLUR) Crypto Forecast: Down 5.7% Today

Curve DAO Token ($CRV) Crypto Forecast: Down 10.3% Today

Maker ($MKR) Crypto Forecast: Down 7.4% Today

Johnson & Johnson Price History

15.09.2024 - JNJ Stock was up 2.8%

• Johnson & Johnson reported impressive Q3 earnings with both revenue and EPS beating expectations, driven by strong sales of cancer drugs.
• The revision of annual outlook to reflect the V-Wave acquisition also contributed to the positive sentiment surrounding the stock.
• Analysts revising their forecasts ahead of the earnings call and high-rolling investors positioning themselves bullish on JNJ further added to the optimism in the market.
• The overall positive earnings report and strategic acquisitions seem to have fueled investor confidence, leading to the bullish movement in Johnson & Johnson's stock price today.

26.05.2023 - JNJ Stock was down 1.2%

• JMG Financial Group Ltd. reduced its position in JNJ by 4.2%, which could have contributed to the bearish movement.
• Mayflower Financial Advisors LLC increased its stake in JNJ by 7.1%, which could have offset the bearish movement.
• The news about BlackRock's control over companies, including JNJ, may have caused uncertainty and contributed to the bearish movement.
• The article about the AI tool that beat out top Wall Street analysts may have also caused investors to question the value of traditional analysis methods and contributed to the bearish movement.

06.08.2023 - JNJ Stock was down 2.3%

• The bearish movement of JNJ stock today can be attributed to the following factors:
• 1. Market sentiment: The overall market sentiment might be bearish, leading to a decline in JNJ stock along with other stocks.
• 2. Cidara Therapeutics announcement: The news about Cidara Therapeutics announcing Janssen's election to proceed under its license agreement relating to novel drug-Fc conjugates targeting influenza may have impacted JNJ stock negatively. This announcement could indicate potential competition in the influenza treatment market, affecting investor confidence in JNJ's pharmaceutical division.
• 3. Idorsia deal with Janssen Biotech: The news of Idorsia reaching a deal with Janssen Biotech, affiliated with Johnson & Johnson, for the return of rights for Aprocitentan might have caused some uncertainty among investors. This deal could have implications for JNJ's future drug development pipeline and potentially affect its revenue prospects.
• 4. Arm's IPO ambitions: The news of Arm halving its IPO ambitions to $4.87 billion, surpassing the listing of Johnson & Johnson consumer health spinoff Kenvue, could have indirectly impacted JNJ stock. This news might have shifted investor attention away from JNJ, leading to a decline in its stock price.
• Overall, the bearish movement of JNJ stock today could be influenced by a combination of market sentiment, competition in the influenza treatment market, uncertainty surrounding future drug development, and the diversion of investor attention to other IPOs.

19.06.2023 - JNJ Stock was down 0.3%

• JNJ stock experienced a strong bearish movement today.
• The company was ordered to pay $18.8 million in a talc-related trial, adding to the ongoing litigation surrounding its baby powder.
• JNJ joined other pharmaceutical companies in taking legal action against the U.S. government's drug pricing negotiation program, which could potentially impact the company's profits.
• Despite the bearish movement, Wealth Enhancement Advisory Services LLC showed confidence in JNJ's growth potential by increasing its holdings in the company during the first quarter.
• Overall, the negative legal developments and concerns over potential profit limitations due to the drug pricing negotiation program likely contributed to the bearish movement in JNJ stock today.

20.06.2023 - JNJ Stock was up 4.4%

• The bullish movement in JNJ stock today can be attributed to the following factors:
• 1. Strong Q2 Earnings: Johnson & Johnson reported better-than-expected Q2 earnings, with adjusted earnings per share of $2.80, beating the consensus of $2.62. Sales also increased by 6.3% to $25.5 billion, surpassing the consensus of $24.63 billion. This positive financial performance likely contributed to the bullish market movement.
• 2. Positive Jobs Data: The Australian job market showed better-than-expected results, with an addition of 32.6K jobs, surpassing the expected 15.4K. This positive employment data may have had a spillover effect on JNJ stock, as it indicates a strong economy and potential increased demand for healthcare products.
• 3. Overall Market Sentiment: The broader market sentiment, with the Dow industrial average rising for the 8th consecutive day and the S&P index and Dow industrial average having risen 7 of the last 8 trading days, may have also influenced the bullish movement in JNJ stock.
• 4. DARZALEX Sales: Genmab reported strong worldwide net trade sales of DARZALEX, a product co-developed with Johnson & Johnson. This positive sales report may have indirectly impacted the market sentiment towards JNJ stock.
• Overall, the combination of strong earnings, positive jobs data, favorable market sentiment, and positive sales reports contributed to the bullish movement in JNJ stock today.

17.06.2024 - JNJ Stock was up 4.1%

• JNJ stock showed strong bullish momentum even as the company adjusted its guidance downwards.
• The positive market response could be linked to Johnson & Johnson surpassing earnings expectations, although the stock price dropped due to revised guidance.
• Investor attention may be directed towards JNJ's consistent growth and diverse business model, factors that have historically contributed to the company's ability to navigate different market environments successfully.
• Despite concerns about the revised guidance, JNJ's history of steady earnings growth and sustainable dividend yield may be providing reassurance to investors and fueling the upward trend in the stock.